Nasdaq · CIK 0000719135
APYX Apyx Medical Corp
Insider trading from SEC Form 4. Last filing Jun 17, 2026.
Apyx Medical Corp (APYX) has 26 SEC Form 4 filings on file from 8 insiders, the latest filed on Jun 17, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Apyx Medical Corp, scored.
Transactions
Every row filed, 30 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Shawn David Roman Chief Operating Officer | MOption exercise Common Stockindirect: By The Roman Family Revocable Trust | +15,000 | $3.23 | $48k | 15,000 | Jun 17, 2026 |
| Jun 15, 2026 | Shawn David Roman Chief Operating Officer | FTax withholding Common Stockindirect: By The Roman Family Revocable Trust | -10,533 | $4.60 | $48k | 16,467 | Jun 17, 2026 |
| Jun 15, 2026 | Shawn David Roman Chief Operating Officer | MOption exercise Stock option (right to buy)derivative | -15,000 | $0.00 | $0 | 0 | Jun 17, 2026 |
| Jun 11, 2026 | Stavros G. Vizirgianakis director | AGrant or award Restricted Stock Units | +450,000 | $0.00 | $0 | 2,196,191 | Jun 15, 2026 |
| Jun 11, 2026 | Wendy Lauren Levine director | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 15, 2026 |
| Jun 11, 2026 | Charles D. Goodwin II Chief Executive Officer | AGrant or award Stock Option (Option to Buy)derivative | +213,948 | $0.00 | $0 | 213,948 | Jun 15, 2026 |
| Jun 11, 2026 | Shawn David Roman Chief Operating Officer | AGrant or award Stock Option (Option to Buy)derivative | +88,044 | $0.00 | $0 | 88,044 | Jun 15, 2026 |
| Jun 11, 2026 | Minnie Baylor-Henry director | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 15, 2026 |
| Jun 11, 2026 | Lawrence Waldman director | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 15, 2026 |
| Jun 11, 2026 | Matthew C Hill Chief Financial Officer | AGrant or award Stock Option (Option to Buy)derivative | +132,066 | $0.00 | $0 | 132,066 | Jun 15, 2026 |
| Jun 11, 2026 | Moshe Citronowicz Sr. V.P. of Operations | AGrant or award Stock Option (Option to Buy)derivative | +63,392 | $0.00 | $0 | 63,392 | Jun 15, 2026 |
| Mar 15, 2026 | Moshe Citronowicz Senior Vice President | MOption exercise Common Stock | +37,000 | $1.80 | $67k | 493,504 | Mar 17, 2026 |
| Mar 15, 2026 | Moshe Citronowicz Senior Vice President | MOption exercise Stock option (right to buy)derivative | -37,000 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Jan 27, 2026 | Shawn David Roman Chief Operating Officer | MOption exercise Common Stockindirect: By The Roman Family Revocable Trust | +12,000 | $1.80 | $22k | 12,000 | Jan 29, 2026 |
| Jan 27, 2026 | Shawn David Roman Chief Operating Officer | MOption exercise Stock option (right to buy)derivative | -12,000 | $0.00 | $0 | 0 | Jan 29, 2026 |
| May 15, 2025 | Minnie Baylor-Henry director | AGrant or award Stock Option (Option to Buy)derivative | +59,000 | $0.00 | $0 | 59,000 | May 19, 2025 |
| May 15, 2025 | Lawrence Waldman director | AGrant or award Stock Option (Option to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | May 19, 2025 |
| May 15, 2025 | Stavros G. Vizirgianakis director | AGrant or award Stock Option (Option to Buy)derivative | +128,000 | $0.00 | $0 | 128,000 | May 19, 2025 |
| May 15, 2025 | Wendy Lauren Levine director | AGrant or award Stock Option (Option to Buy)derivative | +64,000 | $0.00 | $0 | 64,000 | May 19, 2025 |
| May 15, 2025 | Matthew C Hill Chief Financial Officer | AGrant or award Stock Option (Option to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | May 19, 2025 |
| May 15, 2025 | Charles D. Goodwin II Chief Executive Officer | AGrant or award Stock Option (Option to Buy)derivative | +193,000 | $0.00 | $0 | 193,000 | May 19, 2025 |
| May 15, 2025 | Moshe Citronowicz Sr. V.P. of Operations | AGrant or award Stock Option (Option to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | May 19, 2025 |
| Jan 15, 2025 | Minnie Baylor-Henry director | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
| Jan 15, 2025 | Moshe Citronowicz Sr. V.P. of Operations | AGrant or award Stock Option (Option to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Jan 17, 2025 |
| Jan 15, 2025 | Charles D. Goodwin II Chief Executive Officer | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
| Jan 15, 2025 | Matthew C Hill Chief Financial Officer | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
| Jan 15, 2025 | Wendy Lauren Levine director | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
| Jan 15, 2025 | Shawn David Roman Chief Operating Officer | AGrant or award Stock Option (Option to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 17, 2025 |
| Jan 15, 2025 | Stavros G. Vizirgianakis director | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
| Jan 15, 2025 | Lawrence Waldman director | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Minnie Baylor-Henrydirector
- Moshe CitronowiczSr. V.P. of Operations
- Charles D. Goodwin IIChief Executive Officer
- Matthew C HillChief Financial Officer
- Wendy Lauren Levinedirector
- Shawn David RomanChief Operating Officer
- Stavros G. Vizirgianakisdirector
- Lawrence Waldmandirector
Questions about APYX
Answered from the filings on this page, as of the latest one.
Are insiders buying APYX?
No. In the last 90 days no insider at Apyx Medical Corp bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade APYX on the open market?
No open-market trade has been scored at Apyx Medical Corp. The latest Form 4 on file was filed on Jun 17, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Apyx Medical Corp?
8 people have filed a Form 4 at Apyx Medical Corp, among them Minnie Baylor-Henry (director), Moshe Citronowicz (Sr. V.P. of Operations), Charles D. Goodwin II (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.